{"name":"Zhejiang Echon Biopharm Limited","slug":"zhejiang-echon-biopharm-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GB001 recombinant peptide spray","genericName":"GB001 recombinant peptide spray","slug":"gb001-recombinant-peptide-spray","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"}]}],"pipeline":[{"name":"GB001 recombinant peptide spray","genericName":"GB001 recombinant peptide spray","slug":"gb001-recombinant-peptide-spray","phase":"phase_2","mechanism":"GB001 recombinant peptide spray is a recombinant peptide that targets the underlying cause of a specific disease.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}